Skip to main content

Table 1 Characteristics of breast cancer cases and controls, matched on age, menopausal status, and MBI year

From: Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study

Characteristic

Breast cancer cases (n = 62)

Controls (n = 179)

p value

Age at MBI,ayears

60.3 ± 10.6 (38–86)

60.2 ± 10.6 (38–88)

0.88

Menopausal status

  

N/Ab

 Premenopausal

13 (21)

38 (21)

 

 Postmenopausal

49 (79)

141 (79)

 

BMIa

27.7 ± 6.4 (18.8–55.5)

26.2 ± 4.6 (18.6–44.3)

0.08

Postmenopausal systemic HRTc

  

0.57

 Current use at MBI

13 (27)

44 (31)

 

 No current use at MBI

36 (73)

97 (69)

 

BI-RADS density

  

0.77

 Almost entirely fat

1 (2)

3 (2)

 

 Scattered fibroglandular densities

10 (16)

34 (19)

 

 Heterogeneously dense

44 (71)

114 (64)

 

 Extremely dense

7 (11)

26 (15)

 

 Unknown

0

2 (1)

 

Percentage densitya

24.8 ± 8.3 (3.5–48.0)

24.6 ± 10.2 (1.8–53.8)

0.92

MBI protocol

  

0.88

 740 MBq Tc-99m sestamibi

36 (58)

102 (57)

 

 240–300 MBq of Tc-99m sestamibi

26 (42)

77 (43)

 

Tumor invasiveness

   

 Invasive

45 (73)

NA

 

 DCIS

17 (27)

NA

 

Gail model 5-year riska

2.7 ± 1.5 (0.6–7.2)

2.4 ± 1.5 (0.5–9.5)

0.23

BCSC model 5-year riska

2.6 ± 1.2 (0.7–5.4)

2.3 ± 1.5 (0.4–13.2)

0.29

Family history of breast cancer

  

0.45

 One or more first-degree relatives

33 (53)

86 (48)

 

 No first-degree relatives

29 (47)

93 (52)

 

Personal history of biopsy showing atypia or LCIS

  

0.07

 Yes

6 (10)

6 (3)

 

 No

56 (90)

173 (97)

 
  1. BCSC Breast Cancer Surveillance Consortium, BI-RADS Breast Imaging-Reporting and Data System, BMI body mass index, DCIS ductal carcinoma in situ, HRT hormone replacement therapy, LCIS lobular carcinoma in situ, MBI molecular breast imaging
  2. Note: Unless otherwise noted, data are number of patients and data in parentheses are percentages
  3. aData are mean ± SD. Data in parentheses are ranges.
  4. bExact matches
  5. cData are among postmenopausal women only (49 breast cancer cases, 141 controls)